Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ).
Sihuan Pharmaceutical Holdings Group Ltd. announced that its subsidiary, Xuanzhu Biopharma, is considering the implementation of H share full circulation. This involves converting approximately 68.97% of its unlisted shares into H shares, pending approval from the China Securities Regulatory Commission. The move is aimed at enhancing the liquidity and marketability of Xuanzhu Biopharma’s shares, although the listing details on the Hong Kong Stock Exchange are yet to be finalized.
The most recent analyst rating on (HK:0460) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Sihuan Pharmaceutical Holdings Group stock, see the HK:0460 Stock Forecast page.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group Ltd. is a company incorporated in Bermuda, operating in the pharmaceutical industry. It focuses on the development and commercialization of pharmaceutical products, with a market presence in Hong Kong through its subsidiary Xuanzhu Biopharmaceutical Co., Ltd.
Average Trading Volume: 62,203,650
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.34B
Find detailed analytics on 0460 stock on TipRanks’ Stock Analysis page.